SNAP-8

SNAP-8 is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 1 labelled variant: 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, SNAP-8 sits alongside Retatrutide, Tesamorelin, and Ipamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, SNAP-8 is generally treated as an octapeptide analog of the N-terminal domain of SNAP-25 (Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂) studied as a competitive inhibitor of SNARE complex assembly in neuroendocrine secretion assay models. SNAP-25 is a core member of the SNARE (soluble NSF attachment protein receptor) complex — alongside syntaxin-1A and VAMP-2 — that drives neurotransmitter vesicle fusion at the presynaptic membrane. SNAP-8 is a truncated octapeptide corresponding to the N-terminal region of SNAP-25 and competitively inhibits SNARE complex formation by occupying the binding interface before the full ternary complex assembles. In neuroendocrine cell models (e.g., PC12 cells or primary neuronal cultures), SNAP-8 reduces catecholamine vesicle exocytosis in a concentration-dependent manner, validated by catecholamine release assays (amperometry, ELISA). This mechanism makes SNAP-8 a research tool for studying vesicle fusion kinetics and SNARE inhibition specificity versus botulinum toxin-based SNAP-25 cleavage.

SNAP-8 is frequently contrasted with botulinum neurotoxin serotype A (BoNT/A) in SNARE research because both reduce neuromuscular transmission but via mechanistically distinct routes — competitive binding versus proteolytic cleavage. This contrast is informative for assay designs examining SNARE complex reversibility and vesicle recycling. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether SNAP-8 behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare SNAP-8 with Retatrutide, Tesamorelin, and Ipamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.